A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children

Clinical Therapeutics

Volumn 40, Issue 8, 2018, Pages 1268-1281

  Nicholson, Erin G ^a   Munoz, Flor M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

antivirals; influenza; novel; RSV; treatment

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; AK 0529; AL 794; ALX 0171; AMANTADINE; ANAFERON; ANTIVIRUS AGENT; ASVASIRAN; BALOXAVIR MARBOXIL; BTA 9881; BTA C 585; CAPLACIZUMAB; EDP 938; ENZAPLATOVIR; ERGOFERON; JNJ 53718678; LANINAMIVIR; LUMICITABINE; MDT 637; OSELTAMIVIR; PC 786; PERAMIVIR; PRESATOVIR; RADAVIRSEN; RI 001; RIBAVIRIN; RIMANTADINE; RV 521; UMIFENOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIS 410; ZANAMIVIR;

DRUG APPROVAL; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA; LICENSING; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; ADOLESCENT; CHILD; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; FEMALE; INFANT; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG DEVELOPMENT; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 85050799094     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2018.06.014     Document Type: Review

References (73)

1. Wardlaw, TM, Johansson, EW, Hodge, MJ, UNICEF. Division of Communication. World Health Organization. Pneumonia: The Forgotten Killer of Children, 2006, UNICEF.
2. Feigin, RD., Feigin & Cherry's Textbook of Pediatric Infectious Diseases. 2009, Elsevier Health Sciences.
3. Ascough, S, Paterson, S, Chiu, C, Induction and subversion of human protective immunity: contrasting influenza and respiratory syncytial virus. Front Immunol, 9, 2018, 323, 10.3389/fimmu.2018.00323.
4. Poehling, KA, Caspard, H, Peters, TR, et al. 2015–2016 Vaccine effectiveness of live attenuated and inactivated influenza vaccines in children in the United States. Clin Infect Dis 66 (2018), 665–672, 10.1093/cid/cix869.
5. Hall, CB, Weinberg, GA, Iwane, MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360 (2009), 588–598, 10.1056/NEJMoa0804877.
6. Ralston, SL, Lieberthal, AS, Meissner, HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 134 (2014), e1474–e1502, 10.1542/peds.2014-2742.
7. Mejias, A, Ramilo, O, New options in the treatment of respiratory syncytial virus disease global burden of RSV disease. J Infect 71:suppl 1 (2015), S80–S87, 10.1016/j.jinf.2015.04.025.
8. Mazur, NI, Martinón-Torres, F, Baraldi, E, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 3 (2015), 888–900, 10.1016/S2213-2600(15)00255-6.
9. Tan, L, Coenjaerts, FEJ, Houspie, L, et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol 87 (2013), 8213–8226, 10.1128/JVI.03278-12.
10. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull, 16, 1986, 7 http://www.ncbi.nlm.nih.gov/pubmed/3732682 Accessed April 13, 2018.
11. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 118 (2006), 1774–1793, 10.1542/peds.2006-2223.
12. Beaird, OE, Freifeld, A, Ison, MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 18 (2016), 210–215, 10.1111/tid.12510.
13. Marcelin, JR, Wilson, JW, Razonable, RR Mayo Clinic Hematology/Oncology, Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 16 (2014), 242–250, 10.1111/tid.12194.
14. National Institute of Health. Home—Clinicaltrials.gov. https://clinicaltrials.gov/, 2017 Accessed March 4, 2018.
15. Falsey, AR, Koval, C, DeVincenzo, JP, Walsh, EE, Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis, 19, 2017, e12657, 10.1111/tid.12657.
16. Fuller, H, Del Mar, C, Immunoglobulin treatment for respiratory syncytial virus infection. Fuller HL, ed. Cochrane Database Syst Rev.(4), 2006, CD004883, 10.1002/14651858.CD004883.pub2.
17. Cromie, KD, Van Heeke, G, Boutton, C, Nanobodies and their use in GPCR drug discovery. Curr Top Med Chem 15 (2015), 2543–2557 http://www.ncbi.nlm.nih.gov/pubmed/26126902 Accessed June 10, 2018.
18. ® as inhaled biotherapeutics for lung diseases. Pharmacol Ther 169 (2017), 47–56, 10.1016/j.pharmthera.2016.06.012.
19. Melero, JA, Mas, V, The pneumovirinae fusion (F) protein: a common target for vaccines and antivirals. Virus Res 209 (2015), 128–135, 10.1016/j.virusres.2015.02.024.
20. Bonfanti, JF, Roymans, D, Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel 12 (2009), 479–487.
21. McKimm-Breschkin, JL, Jiang, S, Hui, DS, Beigel, JH, Govorkova, EA, Lee, N, Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral Res 149 (2018), 118–142, 10.1016/j.antiviral.2017.11.013.
22. DeVincenzo, JP, Whitley, RJ, Mackman, RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371 (2014), 711–722, 10.1056/NEJMoa1401184.
23. Israel, S, Rusch, S, DeVincenzo, J, et al. Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study. Open Forum Infect Dis, 3(suppl 1), 2016, 10.1093/ofid/ofw172.513.
24. Korell, J, Green, B, DeVincenzo, J, Huntjens, D, A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores. Eur J Pharm Sci 109 (2017), S154–S160, 10.1016/j.ejps.2017.05.070.
25. Gottlieb, J, Torres, F, Haddad, T, et al. A phase 2b randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients. J Hear Lung Transplant, 37, 2018, S155, 10.1016/J.HEALUN.2018.01.375.
26. DeVincenzo, JP, McClure, MW, Symons, JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373 (2015), 2048–2058, 10.1056/NEJMoa1413275.
27. Coates, M, Brookes, D, Kim, YI, et al. Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus l protein polymerase inhibitor. Antimicrob Agents Chemother, 2017, 61, 10.1128/AAC.00737-17.
28. Cockerill, GS, Carter, MC, Henderson, E, et al. MEDI 203—A-60444: the discovery and development of a novel inhibitor of RSV. http://oasys2.confex.com/acs/231nm/techprogram/P934050.HTM, 2006 Accessed March 4, 2018.
29. Challa, S, Scott, AD, Yuzhakov, O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother 59 (2015), 1080–1087, 10.1128/AAC.04119-14.
30. DeVincenzo, J, Lambkin-Williams, R, Wilkinson, T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci 107 (2010), 8800–8805, 10.1073/pnas.0912186107.
31. Gottlieb, J, Zamora, MR, Hodges, T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Hear Lung Transplant 35 (2016), 213–221, 10.1016/j.healun.2015.08.012.
32. Heylen, E, Neyts, J, Jochmans, D, Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem Pharmacol 127 (2017), 1–12, 10.1016/j.bcp.2016.09.014.
33. Araujo, GC, Silva, RH, Scott, LP, Araujo, AS, Souza, FP, de Oliveira, RJ, Structure and functional dynamics characterization of the ion channel of the human respiratory syncytial virus (hRSV) small hydrophobic protein (SH) transmembrane domain by combining molecular dynamics with excited normal modes. J Mol Model, 22, 2016, 286, 10.1007/s00894-016-3150-6.
34. Simões, EAF, DeVincenzo, JP, Boeckh, M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 211:suppl 1 (2015), S1–S20, 10.1093/infdis/jiu828.
35. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses 12 (2018), 132–137, 10.1111/irv.12486.
36. Jefferson, T, Jones, MA, Doshi, P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev.(4), 2014, CD008965, 10.1002/14651858.CD008965.pub4.
37. Bouvier, NM, Palese, P, The biology of influenza viruses. Vaccine 26:suppl 4 (2008), D49–D53.
38. Loregian, A, Mercorelli, B, Nannetti, G, Compagnin, C, Palù G, Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci 71 (2014), 3659–3683, 10.1007/s00018-014-1615-2.
39. Center for Drug Evaluation and Research. Information by Drug Class—Influenza (Flu) Antiviral Drugs and Related Information. https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm100228.htm, 2018 Accessed April 15, 2018.
40. Astrahan, P, Arkin, IT, Resistance characteristics of influenza to amino-adamantyls. Biochim Biophys Acta-Biomembr 1808 (2011), 547–553, 10.1016/j.bbamem.2010.06.018.
41. Grohskopf, LA, Sokolow, LZ, Broder, KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2017-18 influenza season. MMWR Recomm Reports 66 (2017), 1–20, 10.15585/mmwr.rr6602a1.
42. Fiore, AE, Fry, A, Shay, D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Reports 60 (2011), 1–24 http://www.ncbi.nlm.nih.gov/pubmed/21248682 Accessed April 11, 2018.
43. Bradley, JS, Blumer, JL, Romero, JR, et al. Intravenous zanamivir in hospitalized patients with influenza. Pediatrics, 2017, 140, 10.1542/peds.2016-2727.
44. Rafalsky, V, Averyanov, A, Bart, B, et al. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. Int J Infect Dis 51 (2016), 47–55, 10.1016/j.ijid.2016.09.002.
45. Zhavbert, ES, Dugina, IL, Épshteĭn, OI, [Immunotropic properties of anaferon and anaferon pediatric]. Antibiot i khimioterapiia = Antibiot chemoterapy [sic] 58 (2013), 17–23.
46. Skarnovich, MA, Emelyanova, AG, Petrova N, V, et al. Activity of Ergoferon against lethal influenza A (H3N2) virus infection in mice. Antivir Ther 22 (2016), 345–351, 10.3851/IMP3115.
47. Kadam, RU, Wilson, IA, Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci 114:2 (2017), 206–214, 10.1073/pnas.1617020114.
48. Kiselev, OI, Maleev, VV, Deeva, EG, et al. Clinical efficacy of Аrbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR. Ter Arkh, 87, 2015, 88, 10.17116/terarkh201587188-96.
49. Higashiguchi, M, Matsumoto, T, Fujii, T, A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Antivir Ther 23:2 (2018), 157–165, 10.3851/IMP3189.
50. Zaraket, H, Saito, R, Japanese surveillance systems and treatment for influenza. Curr Treat Options Infect Dis 8 (2016), 311–328, 10.1007/s40506-016-0085-5.
51. Ishiguro, N, Koseki, N, Kaiho, M, et al. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. J Infect Chemother 24:6 (2018), 449–457, 10.1016/j.jiac.2018.01.013.
52. Murasaka, T, Ikemura, K, Enokiya, T, et al. Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza. J Pharm Heal Care Sci, 3, 2017, 26, 10.1186/s40780-017-0094-7.
53. Heo, YA., Baloxavir: first global approval. Drugs 78:6 (2018), 693–697, 10.1007/s40265-018-0899-1.
54. Portsmouth, S, Kawaguchi, K, Arai, M, Tsuchiya, K, Uehara, T, Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza. Open Forum Infect Dis, 4(suppl 1), 2017, S734-S734, 10.1093/ofid/ofx180.001.
55. Wu, NC, Wilson, IA, Structural insights into the design of novel anti-influenza therapies. Nat Struct Mol Biol 25 (2018), 115–121, 10.1038/s41594-018-0025-9.
56. Koszalka, P, Tilmanis, D, Hurt, AC, Influenza antivirals currently in late-phase clinical trial. Influenza Other Respi Viruses 11 (2017), 240–246, 10.1111/irv.12446.
57. Ali, O, Takas, T, Nyborg, AC, Jensen, KM, Dubovsky, F, Mallory, R, A phase 2a study to evaluate the safety of MEDI8852 in outpatient adults with acute, uncomplicated influenza A. Open Forum Infect Dis, 4(suppl 1), 2017, 10.1093/ofid/ofx163.1352 S519-S519.
58. Cox, F, Kwaks, T, Brandenburg, B, et al. HA antibody-mediated FcγRIIIa activity is both dependent on FcR engagement and interactions between HA and sialic acids. Front Immunol, 7, 2016, 399, 10.3389/fimmu.2016.00399.
59. McBride, JM, Lim, JJ, Burgess, T, et al. Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model. Antimicrob Agents Chemother, 61, 2017, 10.1128/AAC.01154-17 e01154-17.
60. Celltrion to test combo therapy of new flu antibody drug, Tamiflu—Korea Biomedical Review. http://www.koreabiomed.com/news/articleView.html?idxno=1883, 2018 Accessed April 11, 2018.
61. Chan-Hui, PY, Swiderek, KM, Immunological considerations for developing antibody therapeutics for influenza A. Hum Vaccin Immunother 12 (2016), 474–477, 10.1080/21645515.2015.1079676.
62. Ramos, EL, Mitcham, JL, Koller, TD, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211 (2015), 1038–1044, 10.1093/infdis/jiu539.
63. Beigel, JH, Tebas, P, Elie-Turenne, MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5 (2017), 500–511, 10.1016/S2213-2600(17)30174-1.
64. Semenova NP, Prokudina EN, Livov DK, Nebol'sin VE. [Effect of the antiviral drug Ingaviruin on intracellular transformations and import into the nucleus of influenza A virus nucleocapsid protein]. Vopr Virusol. 55:17-20.
65. Kolobukhina L, V, Merkulova, LN, Shchelkanov, MI, et al. [Efficacy of ingavirin in adults with influenza]. Ter Arkh 81 (2009), 51–54.
66. Trevejo, JM, Asmal, M, Vingerhoets, J, et al. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther., December 2017, 10.3851/IMP3212.
67. Shaw, ML, The next wave of influenza drugs. ACS Infect Dis 3 (2017), 691–694, 10.1021/acsinfecdis.7b00142.
68. Haffizulla, J, Hartman, A, Hoppers, M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 14 (2014), 609–618, 10.1016/S1473-3099(14)70717-0.
69. Chan, RW, Chan, MC, Wong, AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 53 (2009), 3935–3941, 10.1128/AAC.00389-09.
70. Zenilman, JM, Fuchs, EJ, Hendrix, CW, et al. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res 123 (2015), 114–119, 10.1016/j.antiviral.2015.09.008.
71. Moss, RB, Hansen, C, Sanders, RL, Hawley, S, Li, T, Steigbigel, RT, A Phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206:12 (2012), 1844–1851, 10.1093/infdis/jis622.
72. Beigel, JH, Voell, J, Muñoz, P, et al. Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. Br J Clin Pharmacol 84 (2018), 25–34, 10.1111/bcp.13405.
73. Hayden, FG, Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respi Viruses 7 (2013), 63–75, 10.1111/irv.12045.